SCHEMBL25255909

SCHEMBL25255909

COC(=O)c1ccc(-n2nc(C)cc2OC)cc1

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
POLB P06746 1/20 0.61
L3MBTL1 Q9Y468 2/20 0.53
ALDH1A1 P00352 2/20 0.53
MAPT P10636 4/20 0.51
KDM5A P29375 1/20 0.51
KDM4C Q9H3R0 1/20 0.51
KDM5B Q9UGL1 1/20 0.51
RAB9A P51151 2/20 0.50
HPGD P15428 2/20 0.50
GAA P10253 2/20 0.50
LMNA P02545 2/20 0.48
CYP1A2 P05177 1/20 0.48
CYP3A4 P08684 1/20 0.48
CYP2C9 P11712 1/20 0.48
TSHR P16473 1/20 0.48
MAPK1 P28482 1/20 0.48
CYP2C19 P33261 1/20 0.48
KLF5 Q13887 1/20 0.48
TDP1 Q9NUW8 2/20 0.48
KDM4A O75164 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31420389 0.87 POLB (0.63) POLBL3MBTL1ALDH1A1MAPTKDM5A
SCHEMBL25298082 0.84 KDM4A (0.55) POLBL3MBTL1ALDH1A1MAPTRAB9A
SCHEMBL25286098 0.81 ALDH1A1 (0.48) POLBALDH1A1MAPTHPGDLMNA
SCHEMBL31420342 0.79 ALDH1A1 (0.50) L3MBTL1ALDH1A1MAPTRAB9AHPGD
SCHEMBL25248202 0.77 ALDH1A1 (0.53) L3MBTL1ALDH1A1MAPTRAB9AHPGD
SCHEMBL8593786 0.76 POLB (0.71) POLBL3MBTL1ALDH1A1MAPTKDM5A
SCHEMBL21863536 0.76 POLB (0.70) POLBALDH1A1MAPTKDM5AKDM4C
SCHEMBL25791965 0.76 POLB (0.65) POLBL3MBTL1ALDH1A1MAPTKDM5A
SCHEMBL25293276 0.75 ALDH1A1 (0.55) POLBL3MBTL1ALDH1A1MAPTRAB9A
SCHEMBL25290446 0.73 ALDH1A1 (0.53) POLBL3MBTL1ALDH1A1MAPTRAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2025059469-A1 SUBSTITUTED AMINOPYRIDINE COMPOUNDS AS AKT INHIBITORS ATAVISTIK BIO, INC. (US) 2025-03-20 WO disclosed
US-20230219965-A1 NITROGEN-CONTAINING FUSED BICYCLIC COMPOUNDS AND THEIR USE AS UBIQUITIN-SPECIFIC-PROCESSING PROTEASE 1 (USP1) INHIBITORS KSQ Therapeutics, Inc. 2023-07-13 US disclosed
US-20230219965-A1 NITROGEN-CONTAINING FUSED BICYCLIC COMPOUNDS AND THEIR USE AS UBIQUITIN-SPECIFIC-PROCESSING PROTEASE 1 (USP1) INHIBITORS KSQ Therapeutics, Inc. 2023-07-13 US disclosed
US-20230219965-A1 NITROGEN-CONTAINING FUSED BICYCLIC COMPOUNDS AND THEIR USE AS UBIQUITIN-SPECIFIC-PROCESSING PROTEASE 1 (USP1) INHIBITORS KSQ Therapeutics, Inc. 2023-07-13 US disclosed
EP-4161494-A1 NITROGEN-CONTAINING FUSED BICYCLIC COMPOUNDS AND THEIR USE AS UBIQUITIN-SPECIFIC-PROCESSING PROTEASE 1 (USP1) INHIBITORS KSQ Therapeutics, Inc. (US) 2023-04-12 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230219965-A1 NITROGEN-CONTAINING FUSED BICYCLIC COMPOUNDS AND THEIR USE AS UBIQUITIN-SPECIFIC-PROCESSING PROTEASE 1 (USP1) INHIBITORS USP1, USP8, USP7 POLB 3286/4885L3MBTL1 499/4885ALDH1A1 2350/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.